Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Cash (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Change in Cash for 6 consecutive years, with $9.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash fell 66.94% to $9.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.8 million, a 236.78% increase, with the full-year FY2025 number at $19.8 million, up 236.78% from a year prior.
  • Change in Cash was $9.0 million for Q4 2025 at GeneDx Holdings, down from $21.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $424.8 million in Q3 2021 to a low of -$93.3 million in Q3 2022.
  • A 5-year average of -$648550.0 and a median of -$21.2 million in 2022 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 37167.97% in 2021; the steepest drop was 5645.63% in 2021.
  • GeneDx Holdings' Change in Cash stood at -$60.7 million in 2021, then decreased by 11.07% to -$67.4 million in 2022, then soared by 118.36% to $12.4 million in 2023, then surged by 120.67% to $27.3 million in 2024, then tumbled by 66.94% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Change in Cash are $9.0 million (Q4 2025), $21.8 million (Q3 2025), and -$25.6 million (Q2 2025).